全文获取类型
收费全文 | 87602篇 |
免费 | 6110篇 |
国内免费 | 2364篇 |
专业分类
耳鼻咽喉 | 1787篇 |
儿科学 | 1704篇 |
妇产科学 | 863篇 |
基础医学 | 8426篇 |
口腔科学 | 1631篇 |
临床医学 | 9289篇 |
内科学 | 13231篇 |
皮肤病学 | 711篇 |
神经病学 | 6858篇 |
特种医学 | 1895篇 |
外国民族医学 | 8篇 |
外科学 | 7329篇 |
综合类 | 15973篇 |
现状与发展 | 2篇 |
一般理论 | 4篇 |
预防医学 | 6820篇 |
眼科学 | 1082篇 |
药学 | 7296篇 |
143篇 | |
中国医学 | 9157篇 |
肿瘤学 | 1867篇 |
出版年
2024年 | 268篇 |
2023年 | 1593篇 |
2022年 | 2713篇 |
2021年 | 4116篇 |
2020年 | 3831篇 |
2019年 | 3551篇 |
2018年 | 3195篇 |
2017年 | 3306篇 |
2016年 | 3138篇 |
2015年 | 2821篇 |
2014年 | 6014篇 |
2013年 | 5765篇 |
2012年 | 5158篇 |
2011年 | 5998篇 |
2010年 | 5286篇 |
2009年 | 4281篇 |
2008年 | 3959篇 |
2007年 | 4073篇 |
2006年 | 3610篇 |
2005年 | 2981篇 |
2004年 | 2425篇 |
2003年 | 2142篇 |
2002年 | 1558篇 |
2001年 | 1369篇 |
2000年 | 1178篇 |
1999年 | 1066篇 |
1998年 | 860篇 |
1997年 | 775篇 |
1996年 | 622篇 |
1995年 | 674篇 |
1994年 | 597篇 |
1993年 | 487篇 |
1992年 | 470篇 |
1991年 | 377篇 |
1990年 | 345篇 |
1989年 | 325篇 |
1988年 | 307篇 |
1987年 | 273篇 |
1986年 | 263篇 |
1985年 | 504篇 |
1984年 | 499篇 |
1983年 | 388篇 |
1982年 | 446篇 |
1981年 | 423篇 |
1980年 | 410篇 |
1979年 | 353篇 |
1978年 | 317篇 |
1977年 | 278篇 |
1976年 | 204篇 |
1975年 | 127篇 |
排序方式: 共有10000条查询结果,搜索用时 109 毫秒
1.
ObjectivesTo confirm what impairments are present in runners with Achilles tendinopathy (AT) and explore the variance of AT severity in an adequately powered study.DesignCase-control study.SettingTwo private physiotherapy clinics in Australia and Spain.ParticipantsForty-four recreational male runners with AT and 44 healthy controls matched by age, height, and weight.Main outcome measuresDemographics, activity (IPAQ-SF), pain and function (VISA-A), pain during hopping (Hop pain VAS), hopping duration, psychological factors (TSK-11, PASS20), and physical tests regarding lower-limb maximal strength and endurance.ResultsBody mass index (BMI), activity, VISA-A, pain, and duration of hopping, TSK-11, PASS20, standing heel raise to failure, seated heel raise and leg extension 6RM, hip extension and abduction isometric torque were significantly different between groups (P < 0.05) with varied effect sizes (V = 0.22, d range = 0.05–4.18). 46% of AT severity variance was explained by higher BMI (β = −0.41; p = 0.001), weaker leg curl 6RM (β = 0.32; p = 0.009), and higher pain during hopping (β = −0.43; p = 0.001).ConclusionRunners with AT had lower activity levels, lower soleus strength, and were less tall. BMI, pain during hopping, and leg curl strength explained condition severity. This information, identified with clinically applicable tools, may guide clinical assessment, and inform intervention development. 相似文献
2.
3.
《Archivos de bronconeumología》2022,58(1):11-21
BackgroundWe aimed to describe the effectiveness and safety of inhaled antibiotics in chronic obstructive pulmonary disease (COPD) patients, as well as the patient profile in which they are usually prescribed and the patient groups that can most benefit from this treatment.MethodsMulticentre retrospective observational cohort study in COPD patients who had received ≥1 dose of inhaled antibiotics in the last 5 years. Clinical data from the two years prior to and subsequent to the start of the treatment were compared. Primary outcome: COPD exacerbations. Secondary outcomes: side effects, symptomatology (sputum purulence, dyspnoea), microbiological profile and pathogen eradication.ResultsOf 693 COPD patients analyzed (aged 74.1; 86.3% men; mean FEV1 = 43.7%), 71.7% had bronchiectasis and 46.6% presented chronic bronchial infection (CBI) by Pseudomonas aeruginosa (PA). After 1 year of treatment with inhaled antibiotics, there was a significant decrease in the number of exacerbations (?33.3%; P < .001), hospital admissions (?33.3%; P < .001) and hospitalization days (?26.2%; P = .003). We found no difference in effectiveness between patients with or without associated bronchiectasis. Positive patient outcomes were more pronounced in PA-eradicated patients. We found a significant reduction in daily expectoration (?33.1%; P = .024), mucopurulent/purulent sputum (?53.9%; P < .001), isolation of any potentially pathogenic microorganisms (PPM) (?16.7%; P < .001), CBI by any PPM (?37.4%; P < .001) and CBI by PA (?49.8%; P < .001). CBI by any PPM and ≥three previous exacerbations were associated with a better treatment response. 25.4% of patients presented non-severe side-effects, the most frequent of these being bronchospasm (10.5%), dyspnoea (8.8%) and cough (1.7%).ConclusionsIn COPD patients with multiple exacerbations and/or CBI by any PPM (especially PA), inhaled antibiotics appear to be an effective and safe treatment, regardless of the presence of bronchiectasis. 相似文献
4.
5.
6.
7.
8.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
9.
10.
目的研究慢阻肺急性加重期患者延迟就医与家庭动力学的相关性,希望能够为慢阻肺急性加重期患者拟定护理措施提供科学依据。方法选取2017年1月-2019年12月我院240例诊断为慢阻肺急性加重期的患者为研究对象。根据患者入院就医的时间进行分组,时间≥24h的延迟就医的患者为观察组,时间<24h的及时就医患者为对照组。结果两组患者在文化水平、家庭年收入、在职状态、医疗保险和婚姻状况和APACHEⅡ评分比较(P<0.05)。观察组患者疾病观念、个性化、系统逻辑和家庭氛围得分比对照组高(P<0.05)。Pearman的相关性分析结果显示:慢阻肺急性加重期患者延迟就医时间与各个层面分数以及家庭动力总分呈现负相关性(P<0.05)。应变量为延迟就医为应变量,患者的一般资料为自变量,经Logistic回归分析结果表明:延迟就医的影响因素为文化水平、家庭动力评分、职业状态、家庭收入、婚姻状况和APACHEⅡ评分。结论慢阻肺急性加重期患者家庭动力总分与疾病观念、个性化、系统逻辑和家庭氛围得分与延迟就医时间呈现负相关性,患者延迟就医的影响因素是家庭动力学评分。 相似文献